- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06581146
Une étude pour vérifier la santé du foie chez les garçons atteints de XLMTM, une maladie musculaire génétique grave (EXCEL)
Une étude épidémiologique non interventionnelle du XLMTM et de l'expression clinique dans le foie
XLMTM (X-linked myotubular myopathy) is a serious genetic muscle condition. It is caused by changes in the MTM1 gene which stops or slows down normal muscle development, causing severe muscle weakness. There is currently no cure for XLMTM. Ongoing care is needed to manage symptoms and prevent further medical problems from this condition.
Recent research shows that individuals with XLMTM often have reduced bile flow which can affect liver and gallbladder health. Bile is a liquid made in the liver that helps digest fat. Ongoing liver health checks may help with the routine care of people with XLMTM.
There is a need to understand liver problems that develop in individuals with XLMTM over time. The main aim of the study is to learn how many boys with XLMTM have new cases of liver problems during the study.
This study is about collecting information only. This is known as an observational study. The individual's doctor decides on treatment, not the study sponsor (Astellas).
In this study, boys under 18 diagnosed with XLMTM will be followed for about 1 year. The health of their liver and gallbladder will be checked about every 6 weeks. This can be done at home, if preferred. A scan called a Fibroscan (also known as transient elastography) will check for signs of scarring in the liver (fibrosis) and the build-up of lipids. It is suggested that each boy will have a Fibroscan when they start the study and another scan when they complete the study.
This study will help understand liver, gallbladder, and bile duct issues in individuals with XLMTM over time. The goal is to improve their care and provide information to use in future clinical studies.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Astellas Gene Therapies
- Numéro de téléphone: 800-888-7704
- E-mail: Astellas.registration@astellas.com
Lieux d'étude
-
-
Ontario
-
Toronto, Ontario, Canada
- Recrutement
- Site CA15001
-
-
-
-
-
Leeds, Royaume-Uni
- Recrutement
- Site GB44006
-
London, Royaume-Uni
- Recrutement
- Site GB44003
-
Oxford, Royaume-Uni
- Recrutement
- Site GB44005
-
-
-
-
California
-
Santa Monica, California, États-Unis, 90401-2072
- Recrutement
- UCLA Neurological Services
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Recrutement
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02115
- Recrutement
- Boston Children's Hospital
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45229
- Recrutement
- Cincinnati Children's Hospital Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19104
- Recrutement
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, États-Unis, 15224
- Recrutement
- UPMC Children's Hospital of Pittsburgh
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84112
- Recrutement
- University of Utah
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Approximately 50 male participants < 18 years of age with genetically confirmed XLMTM will be enrolled at specialist sites.
La description
Inclusion Criteria:
- Participant has a diagnosis of XLMTM resulting from a genetically confirmed mutation in the MTM1 gene based on genetic test reports.
- Participant requires some mechanical ventilatory support (e.g., ranging from 24 hours per day full-time mechanical ventilation, to non-invasive support such as continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) during sleeping hours)
- Participant (as applicable) and/or parent(s)/carer is willing to comply with the recommended schedule of assessments.
Exclusion Criteria:
- Participant is currently enrolled in an interventional study designed to treat XLMTM.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Participants with XLMTM
Pediatric and adolescent participants with XLMTM. |
No investigational drug will be administered to participants in this study. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence rate of cholestasis
Délai: Up to Week 48
|
Calculated as the number of new cases of cholestasis over 48 weeks divided by total duration of follow-up for enrolled participants. |
Up to Week 48
|
|
Point prevalence of cholestasis
Délai: Day 1
|
Point prevalence of cholestasis is defined as the proportion of participants who have had at least 1 case of cholestasis prior to Day 1 (baseline). |
Day 1
|
|
Prevalence of cholestasis
Délai: Up to 1 year
|
Prevalence of cholestasis is defined as the proportion of participants who have had at least 1 case of cholestasis within 1 year of Day 1 (baseline). |
Up to 1 year
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Genetic variants of MTM1
Délai: Up to Week 48
|
The association between genetic variants of MTM1 and cholestasis will be evaluated. |
Up to Week 48
|
|
Risk of cholestasis temporarily associated with environmental modifiers
Délai: Up to Week 48
|
Medication use, immunization history, infectious disease history and dietary habits will be collected. |
Up to Week 48
|
|
Hospitalizations
Délai: Up to Week 48
|
Frequency and reason for hospitalizations will be collected. |
Up to Week 48
|
|
Duration of Hospitalizations
Délai: Up to Week 48
|
Duration of hospitalization visits will be collected. |
Up to Week 48
|
|
Emergency room visits
Délai: Up to Week 48
|
Frequency and reason for visit will be collected. |
Up to Week 48
|
|
Hepatology specialist visits
Délai: Up to Week 48
|
Frequency and reason for visit will be collected. |
Up to Week 48
|
|
Scheduled/unscheduled office visits
Délai: Up to Week 48
|
Frequency and reason for visit will be collected. |
Up to Week 48
|
|
Non-study-specified home healthcare visits
Délai: Up to Week 48
|
Frequency and reason for visit will be collected. |
Up to Week 48
|
|
Surgeries/procedures
Délai: Up to Week 48
|
Frequency and type will be collected. |
Up to Week 48
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Medical Director, Astellas Gene Therapies
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 1600-MA-3536
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .